ImCare Biotech accepted to the National Cancer Institute Investor Initiatives and will showcase technology at the Bio Investor Forum in San Francisco on October 17 and 18.

ImCare Biotech, LLC is a biotechnology company situated in Doylestown, PA. The company’s primary products in development are innovative diagnostic biomarkers as well as developmental drugs for the treatment of liver diseases such as hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). Its leading product, HepatoDetect┬« is a serum based diagnostic immunoassay that is significantly more sensitive and specific in detecting liver cancer than existing generations of immunoassays and is effective for detecting HCC including in its early stages.

The National Cancer Institute (NCI) Small Business Innovation Research (SBIR) Development Center is interested in connecting SBIR funded companies with potential investors and strategic partners to continue the research and commercialization efforts initially funded by NCI. ImCare Biotech has been accepted and awarded funding to present at national/international showcases where they can explore partnering opportunities. This will help ImCare Biotech raise a successful Series A round of investment and/or partnership.

Please reach out to Mina Soryal for any questions at [email protected], 908-812-6168.

www.imcarebiotech.com